TY - JOUR
T1 - SARS-CoV-2 Infection Leads to Neurological Dysfunction
AU - Acharya, Arpan
AU - Kevadiya, Bhavesh D.
AU - Gendelman, Howard E.
AU - Byrareddy, Siddappa N.
N1 - Funding Information:
We thank Michellie Thurman and Robin Taylor for editorial help. The work contained in this study is dedicated to the life and legacy of Ms. Harriet Singer whose philanthropy and dogged spirit enabled this and countless works possible for studies of human brain disease. This work was supported, in part, by R21MH113455, Frances E. Lageschulte and Evelyn B. Weese New Frontiers in Medical Research Fund to SNB and the Carol Swarts, M.D. Emerging Neuroscience Research Laboratory, the Margaret R. Larson Professorship, and the Frances and Louie Blumkin and Harriet Singer Research Foundations. P30MH062261 to HEG and SNB and 1R01AI145542-01A1, P01 DA028555, R01 NS36126, P01 NS31492, 2R01 NS034239, P01 MH64570, P01 NS43985, R01 AG043540, and 1 R56 AI138613-01A1 to HEG.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - A number of neurological disease complications have been seen following infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While most person with COVID-19 respiratory disease demonstrate headache, nausea and vomiting, up to 40% present also experience dizziness, confusion, cerebrovascular disease, muscle pain, ataxia and seizures. Loss of taste and smell, defects in visual acuity and pain occur in parallel. Such central nervous system (CNS) signs and symptoms linked to laboratory-confirmed SARS-CoV-2 infection is often life threatening. Health care providers currently evaluating patients with neurologic symptoms need consider COVID-19 in any differential diagnosis. These considerations will facilitate prompt testing, isolation and prevention of viral transmission speeding best clinical outcomes. [Figure not available: see fulltext.].
AB - A number of neurological disease complications have been seen following infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While most person with COVID-19 respiratory disease demonstrate headache, nausea and vomiting, up to 40% present also experience dizziness, confusion, cerebrovascular disease, muscle pain, ataxia and seizures. Loss of taste and smell, defects in visual acuity and pain occur in parallel. Such central nervous system (CNS) signs and symptoms linked to laboratory-confirmed SARS-CoV-2 infection is often life threatening. Health care providers currently evaluating patients with neurologic symptoms need consider COVID-19 in any differential diagnosis. These considerations will facilitate prompt testing, isolation and prevention of viral transmission speeding best clinical outcomes. [Figure not available: see fulltext.].
KW - Animal models
KW - CNS
KW - COVID-19
KW - Guillain-Barré syndrome
KW - Neurologic manifestations
KW - SARS-CoV-2
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85085285043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085285043&partnerID=8YFLogxK
U2 - 10.1007/s11481-020-09924-9
DO - 10.1007/s11481-020-09924-9
M3 - Article
C2 - 32447746
AN - SCOPUS:85085285043
VL - 15
SP - 167
EP - 173
JO - Journal of NeuroImmune Pharmacology
JF - Journal of NeuroImmune Pharmacology
SN - 1557-1890
IS - 2
ER -